Citi SELL

Citi The Point for Europe Wednesday, 29 July 2026

Jul 29, 202613 pages页

From the report报告摘录GSK Pipeline Execution Risk: £1.9bn cost savings by 2029, 7 assets in 18 indications, >£40bn 2031 sales target; HIV patent cliffs require flawless execution to offset revenue decline.

Read the full report + PDF阅读全文与 PDF

The full summary (4 key points) and the original Citi PDF are for MastermindX Pro members. 完整摘要（4 个要点）与 Citi 原始 PDF 为 MastermindX Pro 会员专享。

Read on MastermindX前往 MastermindX 阅读

Related institutional research相关机构研报

Not investment advice. MastermindX hosts third-party institutional research for reference and education; ratings and views are the authors', not ours. Browse the full Research Vault → 非投资建议。MastermindX 仅收录第三方机构研究，供参考与学习；其中评级与观点均属作者本人。浏览完整研报库 →